Needham & Company LLC Has Lowered Expectations for TransMedics Group (NASDAQ:TMDX) Stock Price

TransMedics Group (NASDAQ:TMDX) had its price objective lowered by Needham & Company LLC from $208.00 to $109.00 in a research report issued to clients and investors on Tuesday, MarketBeat reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s target price would indicate a potential upside of 33.06% from the company’s previous close.

Several other brokerages also recently issued reports on TMDX. Stephens boosted their price objective on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Robert W. Baird began coverage on TransMedics Group in a research note on Tuesday, September 24th. They issued an “outperform” rating and a $200.00 price target for the company. Piper Sandler restated an “overweight” rating and set a $180.00 price objective on shares of TransMedics Group in a research note on Monday, October 7th. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Finally, Morgan Stanley raised their target price on shares of TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $144.80.

TransMedics Group Stock Down 7.4 %

NASDAQ:TMDX opened at $81.92 on Tuesday. The company has a market capitalization of $2.73 billion, a price-to-earnings ratio of 87.15 and a beta of 1.99. TransMedics Group has a one year low of $36.42 and a one year high of $177.37. The stock has a 50-day simple moving average of $144.20 and a 200 day simple moving average of $139.76. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. During the same period in the prior year, the business earned ($0.12) earnings per share. TransMedics Group’s quarterly revenue was up 63.7% on a year-over-year basis. Sell-side analysts predict that TransMedics Group will post 1.22 EPS for the current fiscal year.

Insider Activity at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,180,642.53. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $8,180,642.53. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total value of $438,493.92. Following the transaction, the insider now owns 20,843 shares in the company, valued at $3,089,766.32. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 61,247 shares of company stock valued at $9,518,181 over the last ninety days. Insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC bought a new stake in shares of TransMedics Group in the 2nd quarter valued at approximately $47,000. USA Financial Formulas bought a new stake in TransMedics Group in the third quarter worth $55,000. J.Safra Asset Management Corp increased its position in TransMedics Group by 649.2% during the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after buying an additional 383 shares during the last quarter. Signaturefd LLC raised its holdings in TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after buying an additional 93 shares in the last quarter. Finally, Fidelis Capital Partners LLC bought a new position in TransMedics Group in the 1st quarter worth $35,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.